HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $6 price target.
March 14, 2024 | 10:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearside Biomedical has been reiterated with a Buy rating and a $6 price target by HC Wainwright & Co. analyst Yi Chen.
The reiteration of a Buy rating and maintenance of a $6 price target by a reputable analyst suggests a positive outlook for Clearside Biomedical's stock. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100